Perioperative Immunotherapy the Future of HCC Treatment?

Video
Conference|ASCO Annual Meeting: Gastrointestinal Cancer

Cancer Network spoke with Dr. Ahmed Kaseb about a phase II pilot trial of perioperative immunotherapy for resectable HCC and how the results could change future perioperative treatment of the disease.

Cancer Network spoke with Dr. Ahmed Kaseb about a phase II pilot trial of perioperative immunotherapy for resectable HCC and how the results could change future perioperative treatment of the disease.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Related Content
A World of Research, Care, and Science: Becoming A Radiation Oncologist

A World of Research, Care, and Science: Becoming A Radiation Oncologist

Tim Cortese
March 12th 2025
Article

James B. Yu, MD, MHS, FASTRO, didn’t always envision himself as a radiation oncologist, but now works tirelessly to treat patients and advance research for genitourinary cancers.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Positive Efficacy Noted With Cemiplimab/Chemotherapy in Penile Carcinoma

Positive Efficacy Noted With Cemiplimab/Chemotherapy in Penile Carcinoma

Tim Cortese
February 15th 2025
Article

The phase 2 EPIC trial assessing patients with penile carcinoma met its primary end point of clinical benefit rate, with the lower bound of the confidence interval exceeding the null hypothesis limit.

Lead author, Quirin Zangl, MD, spoke with CancerNetwork about research published in the journal ONCOLOGY focusing on the importance comprehensive geriatric assessment tools for patients with genitourinary carcinomas.

Oncology Peer Review On-The-Go: Value of Geriatric Assessment in Patients With Genitourinary Carcinomas

Matthew Fowler;Quirin Zangl, MD
November 22nd 2021
Podcast

Lead author, Quirin Zangl, MD, spoke with CancerNetwork about research published in the journal ONCOLOGY focusing on the importance comprehensive geriatric assessment tools for patients with genitourinary carcinomas.

The 2025 Genitourinary Cancers Symposium will feature key updates in the management of different bladder, prostate, and kidney cancer populations.

A Look at Upcoming Impactful Presentations at ASCO GU 2025

Russ Conroy;Roman Fabbricatore
February 12th 2025
Article

The 2025 Genitourinary Cancers Symposium will feature key updates in the management of different bladder, prostate, and kidney cancer populations.

Balstilimab Plus Botensilimab Enhances Response in MSS mCRC without Liver Mets

Balstilimab Plus Botensilimab Enhances Response in MSS mCRC without Liver Mets

Kristi Rosa
January 26th 2025
Article

A phase 2 study evaluated the efficacy of balstilimab and botensilimab in patients with MSS metastatic mCRC without liver metastases.